MARC Record from marc_columbia

LEADER: 04327cam a2200601 i 4500
001 10292528
005 20140922152507.0
008 130318s2013 dcuac b 000 0 eng
016 7 $a101621036$2DNLM
019 $a830351867
020 $a9780309269391
020 $a0309269393
035 $a(OCoLC)850372447$z(OCoLC)830351867
035 $a(OCoLC)ocn850372447
035 $a(NNC)10292528
040 $aNLM$beng$erda$cNLM$dNRC$dYDXCP$dIAI$dCGU$dNRZ$dOCLCF$dBEDGE
042 $anlmcopyc
060 00 $a2013 J-834
060 10 $aQV 773
082 04 $a338.4/76151$223
090 $aHD9665.5$b.I578 2013
110 2 $aInstitute of Medicine (U.S.).$bCommittee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products,$eauthor.
245 10 $aCountering the problem of falsified and substandard drugs /$cCommittee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies.
264 1 $aWashington, D.C. :$bNational Academies Press,$c2013.
300 $axxiv, 351 pages :$billustrations, portrait ;$c24 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
504 $aIncludes bibliographical references.
505 0 $aThe effects of falsified and substandard drugs -- The magnitude of the problem -- Causes of falsified and substandard drugs -- Weaknesses in the drug distribution chain -- Detection technology -- An international code of practice for falsified and substandard medicines.
520 $a"The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines"--Publisher's description.
536 $aSupported by the National Academy of Sciences and the U.S. Food and Drug Administration$bHHSF22301024T$g25
650 12 $aCounterfeit Drugs.
650 12 $aFraud$xprevention & control.
650 22 $aDrug Contamination$xprevention & control.
650 22 $aInternational Cooperation.
650 22 $aPharmaceutical Preparations$xstandards.
650 22 $aQuality Control.
650 0 $aPharmaceutical industry.
650 0 $aPharmaceutical industry$xQuality control.
650 0 $aFraud$xPrevention.
650 7 $aFraud$xPrevention.$2fast$0(OCoLC)fst00933790
650 7 $aPharmaceutical industry.$2fast$0(OCoLC)fst01060129
650 7 $aPharmaceutical industry$xQuality control.$2fast$0(OCoLC)fst01060169
650 7 $aMédecins.$2eclas
650 7 $aProduits pharmaceutiques.$2eclas
650 7 $aContrefaçons.$2eclas
650 7 $aDroit international.$2eclas
650 7 $aOrganisation mondiale de la santé.$2eclas
700 1 $aBuckley, Gillian J.,$eeditor.
700 1 $aGostin, Lawrence O.$q(Lawrence Ogalthorpe),$eeditor.
776 08 $iOnline version:$tCountering the problem of falsified and substandard drugs.$dWashington : National Academies Press, 2013$w(OCoLC)839275199
852 00 $boff,sci$hHD9665.5$i.I578 2013g